Navigation Links
Syracuse University researchers discover new way to attack some forms of leukemia
Date:10/28/2008

Each year, some 29,000 adults and 2,000 children are diagnosed with leukemia, a form of cancer that is caused by the abnormal production of white blood cells in the bone marrow. Current treatments rely primarily on killing the cancer cells, which also destroys normal cells. But what if a way could be found to reprogram cancerous cells back into normal cells? A team of Syracuse University researchers believes it may have found a way to do just that.

Led by Michael Cosgrove, assistant professor of biology in SU's College of Arts and Sciences, the team discovered a way to disrupt the protein switch that is a critical component in the process to create white blood cells. Its discoveries could lead to a more effective way to treat some forms of leukemia and revolutionize the approach to treating other forms of cancer. The research was recently published online in the prestigious Journal of Biological Chemistry of the American Society for Biochemistry and Molecular Biology, and is forthcoming in the print edition.

"We believe our discovery is just the tip of the iceberg," Cosgrove says. "Our hope is that from the knowledge we have gained in understanding how these proteins work in normal cells, we will be able to find new ways to treat all types of leukemia. We also think the discoveries will have broad implications in treating other types of cancer."

To understand how white blood cells are produced, one must begin by looking at the genetic code, the DNA, which provides the blueprint for all the life processes that are carried out in cells throughout the body. All of the cells in the body begin as stem cells with the same DNA. If stretched out in one continuous strand, this genetic blueprint would be about two meters long (about six feet), yet cells somehow manage to compact this rather long DNA strand into its nucleus without tangling or disrupting the exact DNA sequence. "It's sort of like stuffing 10,000 miles of spaghetti into a basketball without it tangling or breaking," Cosgrove says. What differentiates a liver cell from a blood cell is how that DNA is compacted or packaged in the cell nuclei, which results in different genes being expressed and leads to the production of specialized cells (white blood cells, liver cells, pancreatic cells, etc.). Proteins control this DNA packaging process.

Cosgrove's research team has spent the past three years studying one of the proteins that regulate the way DNA is packaged when white blood cells are formed. The protein is called the Mixed Lineage Leukemia (MLL) protein. In normal cells, the MLL protein, which contains 3,969 amino acids, combines with three other proteins to create a molecular switch that controls the DNA packaging events required for the formation of white blood cells. In some types of leukemia, the MLL switch is broken, which prevents white blood cells from maturing properly, resulting in a dangerous proliferation of immature white blood cells.

Cosgrove's team identified a tiny component of the MLL proteina peptide sequence that contains just six amino acidsthat is responsible for assembling the MLL molecular switch in normal cells. The team members called this peptide sequence the "Win" motif. They discovered that a synthetic version of this peptide acts like a drug that breaks apart the MLL molecular switch, interrupting a critical enzymatic process that is required to produce white blood cells. When used against an MLL molecular switch that is brokenworking too fastthe peptide drug attacks the protein switch and breaks it apart, which may slow or stop the production of the abnormal white blood cells. This drug may help to reprogram the way DNA is packaged in leukemia cells and help convert the abnormal cells back into normal cells.

"Reprogramming the way DNA is packaged in cancerous cells is a new idea that has the potential to lead to better treatments with fewer side effects," Cosgrove says. "This last year has been fantastic. We have been learning something new about these proteins almost on a daily basis. Our hope is that as we continue to understand how these DNA packaging proteins work, we will find new ways to treat all types of leukemia as well as other diseases."


'/>"/>

Contact: Judy Holmes
jlholmes@syr.edu
315-443-8085
Syracuse University
Source:Eurekalert

Related biology news :

1. Syracuse University partners with Serum Institute of India to develop vaccines for children
2. Syracuse University scientists discover how some bacteria may steal iron from their human hosts
3. Indiana University research at American Public Health Association meeting
4. Ben-Gurion University of the Negev researchers help find that hypnosis can induce synesthesia
5. Northwest climate change is target of $3.2M in grants to University of Oregon
6. Providing toilets, safe water is top route to reducing world poverty: UN University
7. University of Leicester professor adds new perspective to rainforest debate
8. University success at national engineering awards
9. Scent on demand: Hebrew University scientists enhance the scent of flowers
10. University professor stresses links between US Navy sonar and whale strandings
11. US Senate confirms Clemson University engineering Dean Esin Gulari to National Science Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/3/2016)... -- --> --> ... Identification System Market by Component (Hardware and Software), Search ... Government, Healthcare, and Transportation) and Geography - Global Forecast ... to be worth USD 8.49 Billion by 2020 at ... The transformation and technology evolution from the manual process ...
(Date:2/2/2016)... 2016 Checkpoint Inhibitors for Cancer – ... Are you interested in the future of cancer ... inhibitors. Visiongain,s report gives those predictions to 2026 ... level. Avoid falling behind in data or ... revenues those emerging cancer therapies can achieve. There ...
(Date:2/1/2016)... NEW YORK , Feb. 1, 2016  Today, ... Heart Association (AHA) announced plans to develop a first ... cognitive computing power of IBM Watson. In the first ... disease, AHA, IBM (NYSE: IBM ), and Welltok ... metrics and health assessments with cognitive analytics, delivered on ...
Breaking Biology News(10 mins):
(Date:2/4/2016)... CA (PRWEB) , ... February 04, 2016 , ... ... enterprise talent development and compliance training, today announced an interactive FDA compliance ... Playbook™. The RAPS (Regulatory Affairs Professional Society) accredited interactive course on Morf ...
(Date:2/4/2016)... ... February 04, 2016 , ... Shimadzu Scientific ... LC-MS, host live demos and poster sessions, and present on the analysis of ... takes place March 6 to 10 at the Georgia World Congress Center in ...
(Date:2/4/2016)... N.J. , Feb. 4, 2016  CytoSorbents ... immunotherapy leader commercializing its flagship CytoSorb® blood filter ... surgery patients around the world, announced that CEO ... present at the Source Capital Group,s 2016 Disruptive ... update on the company.  Conference ...
(Date:2/4/2016)... 2016 ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV ... commercialization of targeted antiviral therapies, announced today that it ... to be held February 8-9, 2016, at the Waldorf ... Growth & Healthcare Conference, taking place in ... James Sapirstein , Chief Executive Officer of ContraVir, ...
Breaking Biology Technology: